Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17828184 | 0.78 | ACHE (0.64) | SIGMAR1ACHECYP1A2L3MBTL1 | |
| SCHEMBL11850078 | 0.75 | CYP1A2 (0.48) | SIGMAR1ACHECYP1A2 | |
| SCHEMBL30340999 | 0.73 | CHRM5 (0.58) | SIGMAR1CYP1A2 | |
| SCHEMBL3218288 | 0.73 | CHRM5 (0.58) | SIGMAR1CYP1A2 | |
| SCHEMBL12945 | 0.73 | CHRM5 (0.58) | SIGMAR1CYP1A2 | |
| SCHEMBL24378840 | 0.73 | WNT1 (0.34) | CYP1A2CYP2D6ALOX15 | |
| SCHEMBL24378833 | 0.73 | KDM1A (0.39) | CYP1A2CYP2D6ALOX15 | |
| SCHEMBL19805957 | 0.72 | SIGMAR1 (0.47) | SIGMAR1ACHECYP1A2L3MBTL1 | |
| SCHEMBL10261041 | 0.72 | CYP1A2 (0.47) | SIGMAR1ACHECYP1A2 | |
| SCHEMBL24495782 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | KDM1B, KDM1A, KDM2A | SIGMAR1 4425/4885ACHE 2683/4885CYP1A2 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.